Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Chemotherapy. Roswell Park Cancer Institute, Buffalo, NY, United States

Survival: 17.2 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: United States
City/State/Province: Buffalo, NY
Hospital: Roswell Park Cancer Institute
Journal: Link
Date: 5/2010

This study involved patients with castration-refractory prostate cancer. Patients were divided into 2 separate treatment groups. Group A included 33 men with a median age of 68 years. Group B consisted of 38 men with a median age of 67 years.

Group A was treated with the chemotherapy agent docetaxel and the biologic therapy agent ASA404 (also known as Vadimezan), which is targeted to and disrupts the blood vessels in the tumor.

Group B was treated with docetaxel only.

There were 2 treatment-related deaths in group A due to heart attack and neutropenic sepsis (infection). Also reported were grade 4 neutropenia and grade 3 gastrointestinal disorders and cardiac disorders.

In group B, there was 1 treatment-related death due to a cerebrovascular event (stroke). Also reported were grade 4 neutropenia and grade 3 gastrointestinal disorders.

The median overall survival for groups A and B were 17.0 and 17.2 months, respectively.

This study was supported by Antisoma Research, the makers of ASA404.

Correspondence: Dr. Roberto Pili; email:

E-mail to a Friend Email Physician More Information